Tyrosine kinase inhibitor for kidney cancer

Votrient (pazopanib) is indicated for the treatment of advanced renal cell carcinoma (RCC), both as first-line treatment and following previous cytokine therapy.

Pazopanib is a potent inhibitor of multiple tyrosine kinases: vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, platelet-derived growth factor receptors (PDGFR)-α and –β, and stem cell factor receptor (c-KIT). By inhibiting angiogenesis, pazopanib deprives kidney tumour cells of their oxygen supply.

In a randomised, double-blind, multicentre study in 435 patients with locally advanced and/or metastatic RCC, median progression-free survival was 9.2 months with pazopanib 800mg daily compared with 4.2 months on placebo, equating to a 54 per cent relative reduction in the risk of disease progression with pazopanib (p<0.0001).

View Votrient drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases